Heparin-Induced Thrombocytopenia Is a Clinical-Pathological Disorder
A diagnosis of HIT will be made most accurately if HIT is viewed as a "clinical-pathological" syndrome, 4, 5, 13 in which (1) the patient exhibits a clinical profile broadly consistent with HIT, for example, thrombocytopenia and/or thrombosis bearing a temporal relationship with a preceding immunizing exposure to heparin ("clinical") and (2) the patient's serum (or plasma) is shown to contain heparin-dependent platelet-activating antibodies ("pathological"). One recommended framework 14 for defining HIT is a clinical picture judged to be at least intermediate probability (e.g., scoring at least 4 points in the 4Ts pretest probability scoring system [15] [16] [17] ) and detectability of heparindependent, platelet-activating antibodies (e.g., positive serotonin-release assay (SRA) 18, 19 or heparin-induced platelet activation test 20, 21 with a corroborating positive test for anti-PF4/ heparin antibodies by a PF4-dependent immunoassay, most often an enzyme immunoassay (EIA). 22 Clinical Picture of Heparin-Induced Thrombocytopenia: 4Ts Perspective To distinguish HIT from non-HIT thrombocytopenic disorders, it is important to appreciate the clinical picture of HIT, here viewed through a widely used scoring system, the 4Ts (►Table 1). [15] [16] [17] 
Thrombocytopenia
The first "T," Thrombocytopenia, is characterized by largemagnitude declines in the platelet count (usually, at least 50%) that, however, do not usually reach very low values. Indeed, in the 4Ts, 0 points are given for a platelet count value < 10 Â 10 9 /L, and only 1 point for a platelet count result between 10 and 19 Â 10 9 /L, whereas a > 50% platelet count fall with nadir ! 20 Â 10 9 /L scores as 2 points. (Only $10% of patients with HIT develop a platelet count nadir < 20 Â 10 9 /L. 23 ) This (usual) lack of very severe thrombocytopenia probably reflects the fundamental platelet-activating nature of HIT, as other platelet-activating disorders such as DIC are also characterized by moderate thrombocytopenia, whereas destructive thrombocytopenia caused by platelet-reactive autoantibodies or drug-dependent antibodies often reach platelet count nadirs < 20 Â 10 9 /L. 24 Therefore, the magnitude of the platelet count fall is usually not helpful in distinguishing HIT from non-HIT thrombocytopenia in critically ill patients.
Timing
In contrast, the second "T," Timing of onset of thrombocytopenia (or thrombosis) in relation to a proximate (preceding) heparin exposure, is much more useful. Most critically ill patients-whether admitted to ICU immediately postsurgery, or directly from the community with acute illness-evince early-onset thrombocytopenia. Indeed, even with elective surgery, early postoperative thrombocytopenia is expected, with nadir platelet counts between postoperative days 1 and 4 (median, day 2). 25 In contrast, ►Fig. 1 shows "typical-onset" HIT developing in a critically ill postcardiac surgery patient: here, the unexpected thrombocytopenia that began 5 days postsurgery-with intraoperative exposure to unfractionated heparin (UFH) and postoperative thromboprophylaxis with low-molecularweight heparin (LMWH)-places HIT firmly in the differential diagnosis. By day 6, the 4Ts score was 5 points (intermediate probability score); however, the clinicians suspected septicemia (due to increasing white blood count), and HIT was only considered 2 days later when limb ischemia began (4Ts ¼ 7 points [high probability score]). Laboratory studies also showed concomitant HIT-associated DIC.
Point Immunization
Postoperative HIT exhibits a characteristic timeline (all values in parentheses represent median values): early postoperative thrombocytopenia (onset, day 0) followed by expected postoperative (non-HIT) thrombocytopenic nadir (day 2) followed by initial detection of anti-PF4/heparin antibodies (day 4) followed by the beginning of the HIT-associated platelet count fall (day 6) followed by progressive platelet count decline to > 50% (day 8), often complicated by symptomatic throm-bosis (day 10). 26 This characteristic timeline infers a preceding "point immunization," where intra-/early postoperative heparin exposure, coinciding with perioperative PF4 release from activated platelets, together with inflammation, trigger the anti-PF4/heparin immune response. 5
Typical, Rapid, Delayed, and Spontaneous Onset of HIT
The platelet count fall usually begins between days 5 and 10 (inclusive) following the immunizing heparin exposure (day 0). 27 For a patient recently exposed to heparin (within the previous several weeks or months), and who therefore already has circulating HIT antibodies, resumption of heparin can trigger an abrupt platelet count fall, termed "rapid-onset" HIT. 27 Here, the characteristic association with recent (but not remote) preceding heparin exposure reflects the unusual transience of HIT antibodies, which become undetectable a median of 50 to 80 days (depending on the assay performed) following an episode of HIT. 27 The transience of HIT antibodies is striking: we have observed patients whose antibody levels waned-along with platelet count recovery-even as heparin was continued. 28 Of note, any time that HIT antibodies are actively being generated (whether de novo or recurrent) requires at least 5 days postimmunizing heparin exposure (or reexposure) before HIT-related thrombocytopenia can begin. 29 "Delayed-onset" HIT refers to HIT that begins 30 or worsens 4,31 after stopping heparin. These patients can have unusually severe or persisting thrombocytopenia, often accompanied by overt (decompensated) DIC. In such patients, the SRA shows very strong serum-induced platelet activation even in the absence of heparin. 30, 31 The ability of such highly pathogenic antibodies to activate platelets directly helps explain why the patient's thrombocytopenia can begin or worsen without further heparin being given.
"Spontaneous" HIT syndrome indicates a disorder clinically and serologically indistinguishable from HIT except for the absence of a proximate heparin exposure. 32, 33 Approximately half of these patients developed this disorder postorthopedic surgery (during prophylaxis with warfarin or a new oral anticoagulant) 33, 34 and the remaining usually postinfection (perhaps, joint cartilage 33 or negatively charged bacterial walls 35 provide a template for PF4-dependent immunization). Postorthopedic surgery spontaneous HIT syndrome appears to be a high-risk situation for adrenal hemorrhagic necrosis, 34, 36 which if bilateral leads to life-threatening adrenal failure. Sera from spontaneous HIT patients also exhibit strong platelet-activating properties in the absence of heparin. 33 
Thrombosis
The third "T," Thrombosis (or other clinical sequelae of HIT), is an important diagnostic clue for HIT. This is because HIT is strongly associated with thrombosis, both in absolute and relative terms [6] [7] [8] [9] ; in one study, the relative risk for thrombosis ($12) reflected a frequency of venous thromboembolism in HIT of approximately 50% versus a non-HIT background rate of approximately 4%. 9 Although HIT-associated thrombosis occurs at a median of day 10, the range is wide, and many patients develop symptomatic thrombosis at the beginning of the HIT-associated platelet count fall, 37,38 even before criteria for thrombocytopenia are met.
Venous predominates over arterial thrombosis. Most often, lower-limb DVT is observed (sometimes bilateral), whereas upper-limb DVT is strongly associated with intravascular catheter use. 39 Severe HIT-associated DIC can be complicated by microvascular thrombosis (e.g., acral ischemic necrosis despite palpable pulses) (►Fig. 1). Warfarin therapy-resulting in acquired severe protein C (PC) depletion-is a major risk factor for venous limb gangrene, 40, 41 and thus warfarin is contraindicated during the acute (thrombocytopenic) phase of HIT (and vitamin K is indicated if warfarin has already been given). 11, 42 Large-artery thrombosis secondary to platelet-rich "white clots"-the classic picture of HIT recognized > 40 years ago 43 -usually requires urgent thromboembolectomy for limb salvage. 44 Miscellaneous features of HIT 10 include unusual sites of venous thrombosis (adrenal vein thrombosis leading to hemorrhagic necro-sis, 34, 36, 38 mesenteric vein thrombosis, cerebral venous/dural sinus thrombosis 45 ), necrotizing skin lesions at heparin injection sites 46 (and rarely at noninjection sites 10 ), and anaphylactoid reactions 47 that begin within 30 minutes of an intravenous UFH bolus 48 or within 2 hours of subcutaneous injection of LMWH. 49 
HIT-Associated Disseminated Intravascular Coagulation
Approximately 10 to 20% of patients who develop HIT evince overt (decompensated) DIC, as shown by an otherwise unexplained increased international normalized ratio (INR) or absolute/relative hypofibrinogenemia. 10 The pathogenesis includes procoagulant, platelet-derived microparticles 24 and monocyte activation. 50 Patients often exhibit unusually severe thrombocytopenia and microthrombosis (e.g., acral limb ischemia), and patient serum demonstrates strong platelet activation even in the absence of heparin (►Fig. 1).
Other (Differential Diagnosis)
The fourth "T," OTher cause(s) of thrombocytopenia, is also relatively unhelpful in the ICU, since virtually all critically ill patients have plausible non-HIT explanations for their thrombocytopenia. Prospective studies in critically ill patients have found a frequency of thrombocytopenia of approximately 30 to 50%. 12, 51, 52 Accordingly, one might score 0 or 1 point (never 2 points) when evaluating this 4Ts criterion in a critically ill patient.
HIT-Mimicking Disorder: Acute DIC/Hepatic Necrosis-Limb Necrosis Syndrome
Certain HIT-mimicking disorders have been recognized. 53 For example, a postcardiac surgery patient who develops acuteonset and persisting thrombocytopenia, DIC, and multiple organ failure, and who then develops symmetrical peripheral gangrene (i.e., two-or four-limb acral ischemic necrosis) can be misdiagnosed as HIT, particularly since postcardiac surgery patients often test EIA positive. The author has reported several critically ill patients who have developed multiple limb ischemic necrosis postcardiac surgery and has noted the combination of DIC with preceding "shock liver" (also termed "acute hepatic necrosis" or "ischemic hepatitis"). [52] [53] [54] [55] The pathogenesis of microvascular thrombosis reflects profoundly disturbed procoagulant-anticoagulant balance, for example, marked increased in thrombin generation with concomitant severely reduced antithrombin (AT) and PC levels, 54 and is analogous to warfarin-induced venous limb gangrene complicating HIT (►Table 2). ►Table 3 summarizes aggregate data for 15 non-HIT patients who developed microvascular ischemic limb necrosis ("gangrene with pulses") complicating acute DIC; none was given warfarin before onset of limb ischemia. All patients evinced the clinical picture of symmetrical peripheral gangrene, with lower limbs characteristically involved, but fingers/hands also affected in approximately one-third of cases. A preceding clinical picture of "shock liver" was seen in 14/15 (93%) patients, consistent with a pathogenic role of natural anticoagulant depletion associated with severe hepatic dysfunction. Early-Onset and Persisting Thrombocytopenia: Coinciding HIT Is Rare Critically ill patients often develop early-onset thrombocytopenia that persists until death or that resolves with survival. Selleng et al 56 identified 25 patients with so-called "earlyonset and persisting thrombocytopenia" out of 581 prospectively studied postcardiac surgery ICU patients, and found that the frequency of seroconversion to a positive anti-PF4/ heparin EIA did not differ from patients without persisting thrombocytopenia, indicating that the vast majority of seroconversion events are incidental and nonpathogenic. However, if a patient develops a superimposed platelet count fall within the characteristic days 5 to 10 "window" of HIT, 56, 57 and/or associated thrombosis, 58 and plateletactivating antibodies are detectable, 56-58 this would indicate "true" HIT coinciding with thrombocytopenia of critical illness. Given that only approximately 1 to 2% of postcardiac surgery patients develop HIT (i.e., a small subset of the $50-75% who form anti-PF4/heparin antibodies postcardiac surgery 59, 60 ), comparatively few patients would also develop HIT in the setting of early-onset and persisting thrombocytopenia.
Other HIT-Mimicking Disorders in Critically Ill Patients
Other HIT-mimicking disorders 53 include septicemia (e.g., septic endocarditis with embolic strokes), non-HIT PE-associated consumptive coagulopathy, or even catastrophic antiphospholipid syndrome complicating transition from warfarin to LMWH in a patient with antiphospholipid antibodies who becomes pregnant or requires an invasive procedure.
Serological Picture of Heparin-Induced Thrombocytopenia
Platelet Serotonin-Release Assay (Washed Platelet Assay)
The SRA was invented 30 years ago in the laboratory of Prof. John Kelton, 18 and even today remains the "gold standard" for diagnosing HIT, given its high sensitivity and (relatively) high diagnostic specificity for detecting pathological HIT antibodies; in contrast, PF4-dependent immunoassays frequently detect nonpathological antibodies. 22 Our laboratory (McMaster Platelet Immunology Laboratory) performs the SRA at two pharmacological concentrations of heparin (0.1 and 0.3 IU/mL UFH, i.e., conditions where HIT antibody-induced platelet activation is optimal) and suprapharmacologic UFH (100 IU/mL), where HIT antibody-induced platelet activation is characteristically inhibited. 18 We also measure serotonin release at 0 IU/mL UFH (i.e., buffer control); by performing this last reaction condition, we are able to identify those unusually strong HIT sera obtained from patients with delayed-onset HIT, HIT-associated DIC, persisting HIT, and so forth. Even without ongoing heparin exposure, an episode of severe HIT often reaches its peak intensity (platelet count nadir) approximately 10 to 17 days after the proximate immunizing heparin exposure. 4, 10, 30, 31 These patients can fail alternative (nonheparin) anticoagulant therapy that is monitored using the (activated) partial thromboplastin time (PTT), due to the phenomenon of "PTT confounding" (see section, "PTT and INR Confounding"). 
False-Positive Platelet Activation Assays in ICU Patients
Perhaps because of elevated levels of proinflammatory proteins (e.g., fibrinogen), false-positive platelet activation assays employing a platelet aggregation endpoint-such as citrate-anticoagulated platelet-rich plasma 61, 62 or even washed platelets 63 -occur commonly in ICU patients, in comparison with the (washed platelet) SRA. A negative or weak-positive PF4-dependent EIA in such a patient points to a false-positive platelet activation assay. 61,62
False-Positive PF4-Dependent Immunoassays
A far more common problem is that of false-positive EIAs. As a general rule, 50% of referred sera with detectable anti-PF4/ heparin antibodies by EIA do not contain platelet-activating antibodies, and thus represent false-positive assays. 64, 65 The frequency may be even higher (70-80%) in the critically ill, 66,67 perhaps because of more frequent testing in low pretest probability situations, and possibly also because bacterial infection could trigger formation of nonpathogenic 52-55 b Where results are shown as five data points separated by commas, these represent (in order): lowest value, Q1 (first quartile), median, Q3 (third quartile), and highest value. c Twelve patients were postcardiac surgery; one female patient with methicillin-resistant Staphylococcus aureus endocarditis had both cardiogenic shock and septic shock; all patients had renal failure (all but one received some form of dialysis or renal replacement therapy). d Elevated lactate levels and/or acidemia was documented in all patients. Hemodynamic support with vasopressors was common, with intra-aortic balloon pumps used in five patients. e All but one patient reported to have circulating normoblasts (nucleated red blood cells). f For seven patients, the peak INR occurred before onset of limb ischemia, that is, the INR was improving when limb ischemia began. g For all evaluable patients, D-dimer exceeded the upper value for which the laboratory usually reports (e.g., > 20,000 μg/L FEU); for two patients who underwent further quantitation, the peak levels were 44,600 and 26,920 FEU μg/L. h Out of 15, 14 (93%) patients had ALT values > Â 10 the upper limit of normal ("acute ischemic hepatitis" or "shock liver"); the one exception (ALT ¼ 80 U/mL) had other factors (lower-limb DVT; placement of inferior vena cava filter) that likely contributed to acral limb ischemic necrosis. The peak ALT occurred 4 days (median; range, 1, 8) following surgery or admission. i The peak bilirubin occurred 8 days (median; range, 4, 16) following surgery or admission. The percent direct (conjugated) bilirubin ranged from 54 to 95% (median, 60%). j Mild elevations in ALP were seen in most patients that generally did not exceed Â3 the upper limit of normal. The peak ALP occurred 16 days (median; range, 3, 38) following surgery or admission, and typically occurred after the peak ALT. anti-PF4/heparin antibodies. 35 Clinicians must be careful when diagnosing HIT in an ICU patient, especially when the EIA optical density (OD) value is only weakly positive (as increasing OD predicts strongly for presence of plateletactivating antibodies by SRA 65 ).
Prevention of Heparin-Induced Thrombocytopenia in the ICU

Reduced Risk of HIT with LMWH and Fondaparinux
Almost 20 years ago, a substantial reduction in the risk of HIT with LMWH versus UFH was reported, 7 a finding confirmed in meta-analyses. 68, 69 This difference in risk of HIT reflects the combination of an approximate threefold lower immunization risk and-among patients with HIT antibodies-a threefold lower risk of "breakthrough" of thrombocytopenia, among patients treated with LMWH versus UFH. 7, 8 Thus, the overall risk reduction of HIT with LMWH versus UFH is approximately 10-fold (i.e., 2 vs. 0.2% frequency among postoperative patients exposed to prophylactic-dose UFH vs. LMWH for at least 7-10 days), 68 and is probably at least an order of magnitude lower still with fondaparinux versus LMWH. 70 The greater capacity of UFH (vs. LMWH and fondaparinux) to form ultra-large, more immunogenic, complexes with PF4, and for these larger complexes to activate platelets, likely explains differences in HIT risk. 3 Moreover, fondaparinux is much less likely than both UFH and LMWH to potentiate activation of platelets by HIT antibodies. 71 The reduced risk of HIT with LMWH appears to be a drug class effect, since reduced immunization frequency has been observed with enoxaparin, 72 certoparin, 73 and dalteparin. 74 The PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) trial 75 suggested that dalteparin (vs. UFH) prophylaxis reduces risk of HIT in critically ill patients.
PROTECT Randomized Trial: UFH versus Dalteparin in Critically Ill Patients
The PROTECT trial randomized 3,764 ICU patients in multiple medical centers to receive either dalteparin (5,000 IU oncedaily) or UFH (5,000 IU twice-daily), with the primary outcome being proximal-leg DVT (detected by compression ultrasonography). 75 Secondary end points included PE and HIT (confirmed by the McMaster SRA). By intention-to-treat analysis, 12 of 1,873 (0.6%) patients randomized to receive UFH developed HIT, compared with 5 of 1,873 (0.3%) patients randomized to receive dalteparin (hazard ratio, 0.47 [95% CI, 0.16-1.35]; p ¼ 0.16). These reported frequencies of HIT are consistent with the expected 0.3 to 0.5% range reported observed for HIT in critically ill patients.
The HIT Substudy within the PROTECT Trial
A prespecified per-protocol analysis (which excluded patients who already had HIT upon study enrolment) found that significantly fewer patients in PROTECT who received dalteparin versus UFH developed HIT (hazard ratio, 0.27; 95% CI, 0.08-0.98; p ¼ 0.046). 75 We performed a PROTECT substudy 74 evaluating the potential confounding role of incidental (nonstudy) heparin exposure (including heparin administered before study enrolment), as a potential factor explaining anti-PF4/heparin immunization and/or breakthrough of thrombocytopenia. When taking such nonstudy heparin exposures into account, fewer study drug-attributable HITrelated seroconversion and breakthrough events occurred with dalteparin versus UFH (p ¼ 0.020). 74 Moreover, among patients investigated serologically for HIT, those randomized to dalteparin (vs. UFH) were half as likely to test positive for anti-PF4/heparin IgG (13 vs. 27%; p < 0.001). 74 
Dalteparin for Postcardiac Surgery Thromboprophylaxis
Based on the findings of PROTECT trial, our hospital now uses dalteparin for routine postcardiac surgery thromboprophylaxis (first dose [2,500 U], with subsequent doses 5,000 U continued until mobilization/discharge) (►Fig. 1). Observational studies of dalteparin versus UFH by Pouplard et al 76, 77 (►Fig. 2) suggest that the frequency of HIT could be approximately 80% lower (0.5 vs. 2.5%) with dalteparin versus UFH, a finding that corresponds to the aforementioned 73% reduction (i.e., hazard ratio of 0.27) we observed in the per-protocol analysis reported for PROTECT trial. 75 
Dalteparin Thromboprophylaxis in Critically Ill Patients
Dalteparin was selected for study in the PROTECT trial because it was shown not to bioaccumulate when given in prophylactic doses to renally compromised patients (including patients with dialysis-dependent renal failure). 78, 79 This is an important consideration when choosing an agent for thromboprophylaxis in the critically ill patient population. Although the author does not believe that heparin flushes adversely influence the clinical course of severe HIT (vis-à-vis the severe consequences of HIT antibodies that strongly activate platelets even without heparin being present), they should be avoided because of their medical-legal risk. Note also that the proscription against platelet transfusions is only a "suggestion" (i.e., a "weak" recommendation), 11, 81 given that (1) platelet transfusions have not been proven to be deleterious in HIT (rather, two small retrospective studies found no increased thrombotic risk 82, 83 ) and (2) in the ICU a non-HIT diagnosis is much more likely than HIT, and a risk-benefit assessment that includes diagnostic uncertainty would likely favor platelet transfusions for severely thrombocytopenic patients. Inferior vena cava filter use in HIT patients is often associated with DVT progression-including to critical limb ischemia and limb loss 84 -and their use is not recommended.
These treatment principles should not be applied indiscriminately to the critically ill patient, for several reasons. First, thrombocytopenia in an ICU patient is attributable to HIT only in a small minority of patients; thus, the expected risk-benefit profile of therapeutic-dose, nonheparin anticoagulation in a patient with "true" HIT (high thrombosis with low bleeding risk) does not apply in a non-HIT, critically ill patient (high bleeding risk). Second, renal and hepatic dysfunctions are common in critically ill patients, which can lead to anticoagulant accumulation and increased bleeding risk. Third, coagulopathies are common in ICU, which can confound PTT-adjusted DTI therapy (see section, "PTT and INR Confounding").
UFH: Its Advantages in Critically Ill Patients
If only approximately 1% of thrombocytopenic ICU patients have HIT, this infers that switching from heparin to a non-heparin anticoagulant will occur predominantly in non-HIT patients. But heparin is a near-ideal anticoagulant for critically ill patients: it is cleared through nonrenal, nonhepatic mechanisms, its levels can be directly quantitated (anti-factor Xa levels), and it is approved by the U.S. Food and Drug Administration for the "treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation)"; 85 its anticoagulant effects can be reversed quickly with protamine; it is familiar to many clinicians; and it is inexpensive. In contrast, the safety and efficacy of nonheparin anticoagulants, especially in critically ill patients, are unknown and unproven, and are problematic for use in patients with coagulopathies.
PTT and INR Confounding
Confounding of PTT-and INR-monitored anticoagulant therapy results when prolongation of these tests occurs for reasons independent of the anticoagulant being monitored. 55 For example, if a patient has a baseline (preargatroban) PTT that is elevated (e.g., secondary to HIT-associated DIC), there is a real risk that the (postargatroban) PTT will be supratherapeutic, typically triggering (inappropriate) interruption/ reduction of argatroban dosing, 86,87 which given argatroban's short half-life (40-50 minutes), will lead to rapid loss of anticoagulation. PTT confounding can occur with DIC, liver dysfunction, nonspecific inhibitor ("lupus anticoagulant"), or any other factor that prolongs the PTT. 55 INR confounding occurs commonly during argatrobanwarfarin overlap, as argatroban itself prolongs the INR. There are reports of limb loss caused by venous limb gangrene when argatroban treatment was prematurely interrupted (because of an elevated INR) during overlap with warfarin. 55, 88 
Choice of Nonheparin Anticoagulation
Only one anticoagulant, argatroban, is approved and currently marketed to treat HIT in the United States (lepirudin has been discontinued). Ironically, argatroban was never proven safe and effective for treating HIT, as the prospective cohort studies 89,90 used for regulatory approval did not require positive testing for HIT antibodies, and most enrolled patients likely did not have HIT, whereas most of the (historical) controls likely did have HIT, as they were identified from laboratory logs of test-positive patients. Another concern: the limb amputation rate in the argatroban-treated study patients was relatively high (13.7%), 11 perhaps reflecting the aforementioned issue of INR confounding during warfarin overlap. Further, argatroban has undergone minimal formal study in non-HIT patients, a relevant point given that comparatively few ICU patients develop HIT.
Indirect (Antithrombin-dependent) Factor Xa Inhibitors
In the author's opinion, the indirect (AT-dependent) factor Xa inhibitors, danaparoid and fondaparinux, have numerous advantages over argatroban (for review 5, 22 ), and thus the author has mainly treated HIT with danaparoid 91 and (more recently) fondaparinux, 92 with good overall outcomes. A major advantage of danaparoid and fondaparinux is that they are not monitored by a global coagulation test such as the PTT (thus avoiding the problem of PTT confounding); rather, if desired, drug concentrations can be measured directly (as antifactor Xa levels). However, the indirect Xa inhibitors can accumulate in renal insufficiency, and reduced dosing is appropriate in renally compromised patients. Moreover, prophylactic dose (vs. therapeutic dose) should be given in ICU patients, unless thrombosis is proven, or the clinician is reasonably sure that HIT is present (this is especially important given that danaparoid is largely ineffective when given in prophylactic doses for confirmed HIT 93 ). ►Appendix A summarizes my current approach for treating a patient with HIT using fondaparinux. 94 Recent data 95 suggest that clinicianssuch as the author-are increasingly treating patients with suspected HIT with fondaparinux, despite its off-label status for this indication.
